BridgeBio reports $362.4 million in Attruby revenue for 2025

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported preliminary unaudited net product revenue of $362.4 million for Attruby (acoramidis) for the full year 2025, with fourth-quarter revenue of $146.0 million. The company announced these figures at the J.P. Morgan Healthcare Conference.

The transthyretin stabilizer drug has generated 6,629 unique patient prescriptions from 1,632 prescribers as of December 31, 2025. Attruby is approved for treating the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis in adults.

BridgeBio announced a new TTR amyloid depleter antibody program targeting ATTR-CM disease reversal, with clinical trials expected to begin between 2027 and 2028.

The company's Phase 3 FORTIFY study of BBP-418 in LGMD2I/R9 showed a 2.6 point benefit on NSAD relative to placebo at 12 months. Based on these results, the FDA recommended pursuing traditional full approval, and BridgeBio plans to submit a New Drug Application in the first half of 2026.

For encaleret, the company identified more than 1,700 unique ADH1 patients since October 2023 and intends to submit an NDA based on its Phase 3 CALIBRATE trial results in the first half of 2026. BridgeBio will initiate the RECLAIM-HP Phase 3 trial for chronic hypoparathyroidism in summer 2026.

The PROPEL 3 registrational Phase 3 study of infigratinib for children with achondroplasia achieved last patient last visit, with topline results expected by the end of the first quarter 2026.

BridgeBio reported approximately $587.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025.

You May Also Be Interested In

• SpaceX files for 555.56M share IPO at $135/sh
• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Fuerte changes name to Talamore Mining, shares to trade as TALA